1.1.1.86: ketol-acid reductoisomerase (NADP+)

This is an abbreviated version, for detailed information about ketol-acid reductoisomerase (NADP+), go to the full flat file.

Reaction

(2R)-2,3-dihydroxy-3-methylbutanoate
+
NADP+
=
(2S)-2-hydroxy-2-methyl-3-oxobutanoate
+
NADPH
+
H+

Synonyms

2-hydroxy-3-keto acid reductoisomerase, acetohydroxy acid isomeroreductase, acetohydroxy acid reductoisomerase, acetohydroxy-acid isomeroreductase , acetohydroxy-acid reductoisomerase , acetohydroxyacid isomeroreductase, acetolactate reductoisomerase, AHAIR, AHIR, alpha-keto-beta-hydroxylacil reductoisomerase, alpha-keto-beta-hydroxylacyl reductoisomerase, class II ketol-acid reductoisomerase, dehydrogenase, dihydroxyisovalerate (isomerizing), dihydroxyisovalerate dehydrogenase (isomerizing), Icl1p, Ilv5p, ilvC, IlvC-PanE, IlvC1, IlvC2, isomerase, ketol acid reducto-, isomeroreductase, KARI, ketol-acid reductoisomerase, reductoisomerase

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.86 ketol-acid reductoisomerase (NADP+)

Inhibitors

Inhibitors on EC 1.1.1.86 - ketol-acid reductoisomerase (NADP+)

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1,1-cyclopropanedicarboxylic acid
-
i.e. CPCA, inhibition in vivo, effect on pea root length, shoot length, and fermentative metabolism, effects of KARI inhibition effects on other enzymes, such as alcohol dehydrogenase, EC 1.1.1.1, pyruvate dehydrogenase, EC 4.1.1.1, lactate dehydrogenase, EC 1.1.1.27, and alanine aminotransferase, EC 2.6.1.2, overview
1-aminocarbonyl-cyclopropane carboxylate
-
-
1-aminocarbonylcyclopropanecarboxylate
-
-
1-carbamoylcyclopropanecarboxylic acid
-
-
1-cyano-cyclopropane carboxylate
-
-
1-cyano-N-(2,4,5-trichlorophenyl)cyclopropanecarboxamide
-
inhibition rate: 0%
1-cyano-N-(2,4-dichlorophenyl)cyclopropanecarboxamide
-
inhibition rate: 97.04%
1-cyano-N-(2-hydroxyethyl)cyclopropanecarboxamide
-
inhibition rate: 98.92%
1-cyano-N-(2-methylphenyl)cyclopropanecarboxamide
-
inhibition rate: 100%
1-cyano-N-(4-methoxyphenyl)cyclopropanecarboxamide
-
inhibition rate: 3.95%
1-cyano-N-(4-methylphenyl)cyclopropanecarboxamide
-
inhibition rate: 61.21%
1-cyano-N-phenylcyclopropanecarboxamide
-
inhibition rate: 77.23%
1-cyano-N-[(E)-(3,3-dichloroprop-1-yn-1-yl)diazenyl]sulfanylcyclopropanecarboxamide
-
inhibition rate: 100%
1-cyano-N-[2-(trifluoromethyl)phenyl]cyclopropanecarboxamide
-
inhibition rate: 0%
1-cyano-N-[3-(trifluoromethyl)phenyl]cyclopropanecarboxamide
-
inhibition rate: 0%
1-cyano-N-[4-(trifluoromethyl)phenyl]cyclopropanecarboxamide
-
inhibition rate: 0%
1-cyano-N-[[(3-methylcyclopropa-1,2-dien-1-yl)amino]sulfanyl]cyclopropanecarboxamide
-
inhibition rate: 69.81%
1-cyanocyclopropanecarboxylate
-
-
1-cyanocyclopropanecarboxylic acid
1-hydroxycyclopropanecarboxylate
-
-
11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one
-
-
2,3-dihydroxy-3-isovalerate
-
-
2,3-dihydroxy-3-methylbutanoic acid
-
linear noncompetitive inhibitor of both 2-acetolactate and NADPH
2,3-dihydroxy-3-methylbutyrate
-
-
2-(4-benzylpiperazin-1-yl)-N-(3,4-dichlorophenyl)acetamide
2-(4-benzylpiperazin-1-yl)-N-arylacetamide
-
-
2-(4-methoxybenzamido)benzoic acid
-
-
2-dimethylphosphinoyl-2-hydroxyacetate
2-dimethylphosphinoyl-2-hydroxyacetic acid
2-hydroxy-2-methyl-3-oxopentanoate
-
-
2-Hydroxy-2-methylbutyrate
-
0.01 M 45% inhibition
2-Hydroxybutyrate
-
0.01 M, 48% inhibition
2-Hydroxyisovalerate
2-Methyllactate
2-Oxo-3-hydroxyisovalerate
-
0.001 mM, 58% inhibition
2-oxoisovalerate
-
0.01 M, 21% inhibition
2-[2-(4-morpholino)]acetamido-4-methylthiazole
-
-
2-[[(4-methoxyphenyl)carbonyl]amino]benzoic acid
3-aminopyridine-NADP+
-
-
3-hydroxy-2-oxobutanoic acid
3-hydroxy-3-methyl-2-oxobutanoic acid
4,4'-(pentamethylenedioxy)dibenzamidne bis(2-hydroxyethanesulfonate)
4-(2,4-dichlorophenoxy)benzenecarboximidamide
-
-
4-(2-fluorophenoxy)benzenecarboximidamide
-
-
4-(3-chlorophenoxy)benzenecarboximidamide
-
-
4-(4-chlorophenoxy)benzenecarboximidamide
-
-
4-phenoxybenzenecarboximidamide
-
-
arsenite
-
slight inhibition
ascorbic acid
-
slight inhibition with 2-acetolactate as substrate
chlorsulfuron
cyclopropane-1,1-dicarboxylate
cyclopropane-1,1-dicarboxylic acid
-
-
dimethylmalonate
-
slow-binding inhibitor
ethyl 1-cyanocyclopropanecarboxylate
-
inhibition rate: 0%
ethyl 3-hydroxy-2-oxobutanoate
ethyl 3-methyl-3-hydroxy-2-oxobutanoate
ethyl [(2-chlorophenyl)(hydroxy)amino](oxo)acetate
-
-
ethyl [hydroxy(2-methylphenyl)amino](oxo)acetate
-
-
ethyl [hydroxy(4-methylphenyl)amino](oxo)acetate
-
-
ethyl [[4-(cyanomethyl)phenyl](hydroxy)amino](oxo)acetate
-
-
ethylene glycol
-
exhibits competitive and uncompetitive inhibition
HOE 704
IpOHA
L-ascorbic acid
-
slightly inhibitory with alpha-acetolactate as substrate
methyl [hydroxy(1-methylethyl)amino](oxo)acetate
-
-
metsulfuron-methyl
Mn2+
-
with acetolactate as substrate, Mn2+ behaves as a competitive inhibitor in presence of Mg2+
N'-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-(2-methyl-phenyl)-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-(3-methyl-phenyl)-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-(3-pyridinyl)-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-butyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-ethyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-furan-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-heptyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-iso-propyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-isopropyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-methyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
-
N'-(5-octyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-pentyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-phenyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N'-(5-propyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyformyl-thiourea
-
-
N-(2-(piperidin-1-yl)ethyl)phthalimide
-
-
N-(3-bromophenyl)-1-cyanocyclopropanecarboxamide
-
inhibition rate: 17.25%
N-(3-chlorophenyl)-1-cyanocyclopropanecarboxamide
-
inhibition rate: 0%
N-(4-bromophenyl)-1-cyanocyclopropanecarboxamide
-
inhibition rate: 32.23%
N-(4-chlorophenyl)-1-cyanocyclopropanecarboxamide
-
inhibition rate: 93.92%
N-(5-substituted-1,3,4-thiadiazol-2-yl)-N-cyclopropylformyl-thiourea
-
-
N-Hydroxy-N-isopropyloxamate
NADP+
additional information
-